Objective-By excreting cellular cholesterol to apolipoprotein A-I, ATP-binding cassette transporter A1 (ABCA1) mediates the biogenesis of high-density lipoprotein in hepatocytes and prevents foam cell formation from macrophages. We recently showed that cell surface-resident ABCA1 (csABCA1) undergoes ubiquitination and later lysosomal degradation through the endosomal sorting complex required for transport system. Herein, we investigated the relevance of this degradation pathway to the turnover of csABCA1 in hypercholesterolemia. Approach and Results-Immunoprecipitation and cell surface-biotinylation studies with HepG2 cells and mouse peritoneal macrophages showed that the ubiquitination level and degradation of csABCA1 were facilitated by treatment with a liver X receptor (LXR) agonist and acetylated low-density lipoprotein. The effects of an LXR agonist and acetylated lowdensity lipoprotein on the degradation of csABCA1 were repressed completely by treatment with bafilomycin, an inhibitor of lysosomal degradation, and by depletion of tumor susceptibility gene 101, a major component of endosomal sorting complex required for transport-I. RNAi analysis indicated that LXRβ inhibited the accelerated lysosomal degradation of csABCA1 by the LXR agonist, regardless of its transcriptional activity. Cell surface coimmunoprecipitation with COS1 cells expressing extracellularly hemagglutinin-tagged ABCA1 showed that LXRβ interacted with csABCA1 and inhibited the ubiquitination of csABCA1. Immunoprecipitates with anti-ABCA1 antibodies from the liver plasma membranes showed less LXRβ and a higher ubiquitination level of ABCA1 in high-fat diet-fed mice than in normal chow-fed mice. Conclusions-Under conditions of high cellular cholesterol content, csABCA1 became susceptible to ubiquitination by dissociation of LXRβ from csABCA1, which facilitated the lysosomal degradation of csABCA1 through the endosomal sorting complex required for transport system.
A TP-binding cassette transporter A1 (ABCA1) promotes the efflux of cellular cholesterol and phospholipids to apolipoprotein A-I. [1] [2] [3] [4] Its hepatic and intestinal function is essential for the biogenesis of high-density lipoprotein (HDL) and determines plasma HDL levels. 5 HDL has antiatherosclerotic effects, including reverse cholesterol transport, a process coordinated by lecithin cholesterol acyltransferase, ABCA1, and ATP-binding cassette transporter G1, which results in the net movement of cholesterol from peripheral tissues back to the liver. 6, 7 Reverse cholesterol transport contributes to maintain normal cholesterol turnover in the whole body and most of the peripheral cells. ABCA1 prevents foam cell formation from macrophages and the subsequent progression to atherogenesis. 8, 9 The atheroprotective function of ABCA1 in humans is illustrated by the effects of Tangier disease, which is caused by a mutation in the ABCA1 gene and is characterized by an increased susceptibility to atherosclerotic cardiovascular disease. 2 This background has generated great interest in treating atherosclerotic cardiovascular disease by controlling ABCA1.
One rational approach to preventing the progression of atherosclerosis through the role of ABCA1 in hypercholesterolemia and diabetes mellitus is to modulate the turnover of ABCA1. This is because degradation of ABCA1 is facilitated in cells loaded with free cholesterol and unsaturated fatty acids, whose plasma levels are elevated in diabetic people, resulting in reduced ABCA1 expression and apolipoprotein A-I-mediated cholesterol efflux. 10, 11 Although several papers have reported contradictory results, 12, 13 it seems that ABCA1 on the plasma membrane, but not in intracellular compartments, plays a dominant role in apolipoprotein A-I-mediated cholesterol efflux. 14 Therefore, elucidation of the mechanism responsible for degradation of cell surface-resident ABCA1 June 2015 (csABCA1) is considered to be important to understanding the regulation of ABCA1 function.
A key molecule for the degradation of csABCA1 is the protease calpain, which can cleave ABCA1 in the intracellular compartment or at the cell surface. 15, 16 However, calpain seems not to be involved in the accelerated degradation of ABCA1 induced by loading with free cholesterol and unsaturated fatty acids. 10, 11 We recently found another degradation mechanism of csABCA1 that is independent of the calpain protease-involving machinery. Through this mechanism, ubiquitination, a regulated posttranslational modification that conjugates ubiquitin to lysine residues of targeted proteins, acts as a signal for the degradation of csABCA1 by the direction of ubiquitinated csABCA1 to lysosomal degradation. 17 This degradation process involves the endosomal sorting complex required for transport (ESCRT) system, a set of proteins comprising ESCRT-0, -I, -II, and -III, which recognizes ubiquitinated cargo in the early endosome and mediates its recruitment to and incorporation into multivesicular bodies, leading to lysosomal degradation. [18] [19] [20] To explore the possibility of restoring the turnover of csABCA1 and inhibiting progression of atherosclerosis in hypercholesterolemia, in the current study, we focused on the ubiquitination-mediated lysosomal degradation of csABCA1 and investigated the molecular mechanism underlying the degradation of csABCA1 under conditions of high cellular cholesterol content.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Accelerated Degradation of csABCA1 by Liver X Receptor Agonist and Acetylated Low-Density Lipoprotein Loading
We first examined the influence of high cellular cholesterol level on the degradation of csABCA1 because the whole-cell lysate, but not the cell surface fraction, was used to evaluate the degradation of ABCA1 in the previous report. 10 Liver X receptor (LXR), a nuclear receptor, controls cellular cholesterol homeostasis by regulating the expression of the gene responsible for cholesterol homeostasis by sensing oxysterols, oxidized derivatives of cholesterol, which are generated under conditions of high cellular cholesterol content. 21 Therefore, GW3965, an LXR agonist, can induce cellular response to cholesterol accumulation in the cells and was used to examine effects of cholesterol accumulation on the degradation of csABCA1. HepG2 cells and HuH-7 cells both originated from a human hepatoma and endogenously express ABCA1. Mouse peritoneal macrophages (MPM) are a commonly used type of primary macrophage with endogenous ABCA1 expression. After confirming that treatment with GW3965 increased ABCA1 expression in these cells as described previously 22, 23 ( Figure IA in the online-only Data Supplement), effect of GW3965 on the degradation of csABCA1 was evaluated. In all 3 cell types, the cell surface biotinylation study showed that degradation of csABCA1 was accelerated by treatment with GW3965 ( Figure 1A ). The amount of biotin-labeled ABCA1 remaining after incubation at the indicated times in HepG2 cells, HuH-7 cells, and MPM was 30%, 38%, and 30%, respectively, in the GW3965-treated condition. These values were less than the respective values of 56%, 58%, and 61% observed in the untreated condition. Another LXR agonist, T0901317, also had a similar effect on the degradation of csABCA1 (data not shown).
The effect of cholesterol accumulation on the degradation of csABCA1 was investigated further in MPM treated with acetylated low-density lipoprotein (acLDL), which induces cholesterol accumulation and foam cell formation. After confirming that acLDL loading increased ABCA1 expression in MPM as described previously 22 ( Figure IB in the online-only Data Supplement), effect of acLDL loading on the degradation of csABCA1 was evaluated. The cell surface biotinylation study showed faster degradation of csABCA1 in acLDL-treated MPM than in normally cultured MPM ( Figure 1B ). The amount of biotin-labeled ABCA1 remaining 4 hours after incubation was 28% in acLDL-treated MPM compared with 55% in normally cultured MPM.
HepG2 cells, but not HuH-7 cells, were used as the model hepatocyte cell line in further studies because HepG2 cells attach tightly to plates and are easier to handle compared with HuH-7 cells.
Involvement of Lysosomal Degradation Through the ESCRT Machinery in the Accelerated Degradation of csABCA1 Under Conditions of High Cellular Cholesterol Content
We previously demonstrated that csABCA1 undergoes ubiquitination and consequently lysosomal degradation through the ESCRT system, which acts in a coordinated cascade from ESCRT-0 to ESCRT-III. 17 To explore the relationship between this degradation pathway and the increased degradation of csABCA1 under conditions of high cellular cholesterol content, the ubiquitination level of ABCA1 was measured in immunoprecipitates obtained with anti-ABCA1 antibody from the crude membrane fractions of HepG2 cells and MPM. Immunoblot analysis of the immunoprecipitates showed a band of ubiquitinated ABCA1 (ABCA1-Ub) at a slightly higher molecular weight than that of ABCA1 itself, which was detected predominantly as a 260 kDa band. Treatment with the LXR agonist, GW3965, increased the ubiquitination level of ABCA1 by ≈2. 5 MPM, respectively ( Figure 2A ). The ubiquitination level of ABCA1 was also increased in foam cells induced by acLDL loading ( Figure 2B ). The band representing ABCA1-Ub was not detected by anti-ABCA1 antibody in the immunoprecipitates, as we previously observed for BSEP (bile salt export pump) and MRP2 (multidrug resistance-associated protein 2), the other 2 ABC transporters we have studied. 24, 25 This is probably because csABCA1 is readily degraded after undergoing ubiquitination, which could reduce the amount of ABCA1-Ub below the limit of detection by anti-ABCA1 antibody. Bafilomycin, an inhibitor of lysosomal degradation, and depletion of tumor susceptibility gene 101 (TSG101), a major component of ESCRT-I, were used to obtain further insight into the association between lysosomal degradation through the ESCRT machinery and the accelerated degradation of csABCA1 induced by cellular cholesterol accumulation. Bafilomycin canceled the degradation of csABCA1 facilitated by treatment with the LXR agonist, GW3965, in HepG2 cells and MPM, and by acLDL loading in MPM ( Figure 3A and 3B). Together with the fact that MG132, a proteasome inhibitor, did not increase ratio of ABCA1 expression in cell surface fraction to that in whole cell lysate in HepG2 cells treated with LXR agonist (our unpublished data), this result suggests that lysosome-involving pathway mediates csABCA1 degradation independently of the ubiquitin-proteasome system. The accelerated degradation of csABCA1 in HepG2 cells treated with GW3965 was also blocked completely by the depletion of TSG101 ( Figure 3C and 3D). Bafilomycin and depletion of TSG101 did not increase molecular weight of the biotin-labeled ABCA1 in the cells treated with LXR agonist and acLDL, indicating no accumulation of ABCA1-Ub under these culture conditions. It could be considered that ABCA1-Ub internalized from the plasma membrane is deubiquitinated in the early endosome by deubiquitinating enzymes like UBPY (ubiquitin isopeptidase Y) and AMSH (associated molecule with the SH3 domain of STAM) that interact with ESCRT-0. 26, 27 The degradation of csABCA1 was unaffected by bafilomycin and depletion of TSG101 in the cells under normal culture conditions.
Inhibition of Ubiquitination and Lysosomal Degradation of csABCA1 by LXRβ
Recently, an isoform of LXR, LXRβ, was reported to have a function other than as a transcriptional factor that regulates the turnover of whole-cell ABCA1 through its physical interaction with ABCA1. 28 In the absence of an agonist, LXRβ interacted with ABCA1 and inhibited the turnover of whole-cell ABCA1, whereas in the presence of an agonist, the interaction disappeared and LXRβ no longer affected the turnover of whole-cell ABCA1. To explore further the mechanism underlying the accelerated lysosomal degradation of csABCA1 under conditions of high cellular cholesterol content, we examined the involvement of LXRβ in that mechanism.
Degradation of csABCA1 was facilitated by depletion of LXRβ in HepG2 cells treated with actinomycin D, an RNA synthesis inhibitor ( Figure 4A and 4B). The amount of biotinlabeled ABCA1 remaining in LXRβ-depleted HepG2 cells after the 8 hours incubation was 40% ( Figure 4B ), which was similar to the 30% remaining in HepG2 cells treated with the LXR agonist, GW3965 ( Figure 1A ). Taken together with the observation that, in HepG2 cells and MPM depleted of LXRβ, the degradation of csABCA1 was unaffected by the LXR agonist, GW3965 ( Figure 4A and 4C), this result suggested that LXRβ inhibits the accelerated lysosomal degradation of csABCA1 by an LXR agonist in a posttranscriptional manner. Consistently, bafilomycin completely blocked the accelerated degradation of csABCA1 induced by LXRβ depletion in HepG2 cells and MPM ( Figure 4A and 4D) .
As reported previously, 28 the interaction between ABCA1 and LXRβ was confirmed by the presence of FLAG-LXRβ in immunoprecipitates obtained with anti-ABCA1 antibody from COS1 cells expressing 207 HA-ABCA1 (in which hemagglutinin epitope was introduced between G207 and D208 of ABCA1), 29 and FLAG-LXRβ ( Figure 5A ). The results of the cell surface-biotinylation study of COS1 cells expressing 207 HA-ABCA1 and FLAG-LXRβ showed that both proteins were included in the cell surface fraction, as well as in the cell lysate ( Figure 5B ), and suggested that the interaction occurred at the cell surface ( Figure 5B ). Therefore, the effects of LXRβ on ubiquitination of csABCA1 were analyzed using cell surface immunoprecipitation in COS1 cells expressing 207 HA-ABCA1 ( Figure 5C ). In this assay, the cells were subjected to reaction with anti-hemagglutinin antibody before cell lysis, and only cs 207 HA-ABCA1 was precipitated. Immunoblot analysis of the cell surface immunoprecipitation products showed that FLAG-LXRβ interacted with 207 HA-ABCA1 at the cell surface and reduced the ubiquitination level of cs 207 HA-ABCA1 by 38% ( Figure 5C, right) .
Decreased Interaction of ABCA1 With LXRβ and Increased Ubiquitination of ABCA1 in Liver Plasma Membrane Fractions of High-Fat Diet-Fed Mice
The interaction between ABCA1 and LXRβ in the liver plasma membrane fractions (LPM) of mice was indicated by coimmunoprecipitation with anti-ABCA1 antibody ( Figure 6A ). To demonstrate the in vivo relevance of the findings obtained from cells with high cellular cholesterol content, male C57BL/6J mice were maintained on the high-fat diet (HFD) or normal chow, and LPM were prepared. Six months after the onset of the feeding, the HFD-fed group had gained 1.3× as much body weight compared with the normal chow-fed group (Figure 6B and 6C ). Higher cholesterol content was confirmed in the livers of HFD-fed mice than in the normal chow-fed mice ( Figure 6D ). LPM were prepared and subjected to coimmunoprecipitation with anti-ABCA1 antibody. The immunoprecipitates from the LPM of the HFD-fed mice showed less LXRβ and a higher ubiquitination level of ABCA1 compared with those of the normal chow-fed mice ( Figure 6E ). In LPM from HFD-fed mice, no significant change in ABCA1 expression was observed, despite the increased ubiquitination of ABCA1. This is likely to be because of the net outcome of transcriptional induction of ABCA1 mRNA 30, 31 and lysosomal degradation of ubiquitinated csABCA1.
Discussion
ABCA1 acts as an atheroprotective factor through its efflux function for cellular cholesterol and phospholipid in various cells. This function is indispensable for HDL biogenesis in hepatocytes and prevention of foam cell formation from macrophages, thus protecting against atherosclerotic cardiovascular disease. 5, 8, 9 The principal finding of our current study is that, under conditions of high cellular cholesterol content, csABCA1 was more susceptible to ubiquitination and consequently underwent lysosomal degradation through the ESCRT system. This was supported by the observation that the accelerated degradation of csABCA1 in the cells treated with an LXR agonist or acLDL was restored completely by treatment with bafilomycin and depletion of TSG101 (Figure 3 ). In HepG2 cells and MPM transfected with LXRβ short interfering RNA, degradation of csABCA1 was facilitated independently of the transcriptional regulation and was unaffected by treatment with an LXR agonist (Figure 4 ). This finding suggests that LXRβ negatively regulates the ubiquitination-mediated lysosomal degradation of csABCA1 through its posttranscriptional activity. Given that LXRβ interacted with csABCA1 and reduced the ubiquitination level of csABCA1 ( Figure 5C ) and that the interaction between both proteins was lessened by an LXR agonist 28 and cellular cholesterol accumulation ( Figure 6D and 6E) , it is likely that csABCA1 is protected from ubiquitination by its physical interaction with LXRβ. By contrast, cellular cholesterol accumulation seems to dissociate LXRβ from csABCA1, which exposes csABCA1 to a molecular subset that is responsible for ubiquitination of csABCA1, and thereby leads to its lysosomal degradation through the ESCRT system (Figure 7) .
The findings of our study suggest that modulating the ubiquitination of csABCA1 is a preferable option to retarding the progression of atherosclerosis in hypercholesterolemia. The ubiquitination of substrate proteins is mediated by the covalent attachment of ubiquitin via the sequential action of 3 enzymes: a ubiquitin-activating enzyme E1, a ubiquitinconjugating enzyme E2, and a ubiquitin ligase E3. 32 Among these 3 enzymes, E3 is considered the enzyme that ensures the correct timing, localization, and specificity of the ubiquitination reaction because genomic information suggests that there are several hundreds of E3s in eukaryotic cells. 33 A recent report indicated that the COP9 signalosome complex regulates the ubiquitination status of ABCA1. 34 However, it remains unknown whether this complex has the ability to ubiquitinate ABCA1. Further studies are needed to explore in detail the function of the COP9 signalosome complex and to identify and characterize the E3s that localize close to the plasma membrane. 35 These studies should shed light on the molecular mechanism responsible for csABCA1 ubiquitination and may make it possible to modulate the ubiquitination of csABCA1.
From the viewpoint of cell protection, it seems disadvantageous to facilitate degradation of csABCA1 under conditions of high 
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Minor contribution Figure 7 . Proposed model of the molecular mechanism underlying the degradation of cell surface-resident ATP-binding cassette transporter A1 (csABCA1) through ubiquitination. A, In the basal state, csABCA1 is less affected by ubiquitination-mediated lysosomal degradation. Liver X receptor β (LXRβ) interacts with csABCA1 and inhibits the ubiquitination of csABCA1, which functions as a sorting signal to lysosomes in the early endosome. B, In people with hypercholesterolemia, degradation of csABCA1 through ubiquitination is activated. LXRβ binds to its ligands, oxygenated derivatives of cholesterol, and dissociates from csABCA1. Consequently, E3, which is responsible for the ubiquitination of csABCA1, can recognize csABCA1, and this recognition leads to an increase in the ubiquitination of csABCA1 and thereby accelerates its lysosomal degradation through the endosomal sorting complex required for transport (ESCRT) system. Ub indicates ubiquitin. cellular cholesterol because this adaptation decreases expression of csABCA1 and cholesterol efflux by ABCA1, which induces cell toxicity by abnormal deposition of cellular cholesterol. However, given that one of the hepatic functions in cholesterol homeostasis is to eliminate cholesterol from the body by conversion of cholesterol to bile acids and by biliary excretion, 36, 37 the accelerated degradation of hepatic csABCA1 by cholesterol accumulation prevents back flow of cholesterol into systemic circulation and thereby helps efficient cholesterol elimination from the body. This regulatory mechanism is consistent with the previous report showing that ABCA1 expression in liver is modulated not only by normal transcript of ABCA1, but also by its liver-specific transcript whose expression level is suppressed by treatment with sterols. 38 In other somatic cells, including macrophages, the machinery identified in the current study might contribute to suppression of the acute loss of too much cholesterol by ABCA1 because transcription of ABCA1 mRNA is more markedly induced in these cells than in hepatocytes in response to cholesterol accumulation. 22, 39 The hypothesis could be integrated into the model proposed by Hozoji et al showing that the cellular cholesterol accumulation induces emergent activation of ABCA1 function through dissociation of LXRβ from ABCA1. 28 The degradation of csABCA1 is slower event than the functional activation of ABCA1 because it consists of multiple steps after the release of csABCA1 from LXRβ: ubiquitination, endocytosis, sorting to lysosome transport pathway in early endosome, and finally lysosomal degradation. Therefore, the molecular mechanism identified in our study acts to inhibit the acute loss of too much cellular cholesterol by the functional activation of ABCA1. The ubiquitination-mediated lysosomal degradation through the ESCRT system contributed to the degradation of csABCA1 only under conditions of high cellular cholesterol content in HepG2 cells and MPM (Figure 3 ). By contrast, our previous study showed that the degradation of csABCA1 in HuH-7 cells was regulated by this degradation pathway even under normal culture conditions. 17 We currently have no direct evidence to clarify the reason for difference among these cell lines because the abundance ratio of LXRβ to ABCA1 in the crude membrane fractions was similar in HepG2 cells and HuH-7 cells (data not shown). One explanation may involve differences in proteins that affect the interaction between csABCA1 and LXRβ. A recent report showed that ABCA12 can form a protein complex with ABCA1 and LXRβ and thereby modulate the activity and stability of ABCA1 through the function of LXRβ. 40 The interaction between csABCA1 and LXRβ may be modulated by syntrophin, which tethers ABCA1 to the actin cytoskeleton through protein-protein interaction and stabilizes ABCA1 near the plasma membrane. 41, 42 Therefore, it is conceivable that factors regulating the interaction between csABCA1 and LXRβ, whose expression level differs between cell types, determine the contribution of the ubiquitination-mediated lysosomal degradation through the ESCRT system to csABCA1 degradation under conditions of normal cellular cholesterol content.
In conclusion, our present study suggests that cellular cholesterol accumulation interrupts the interaction between csABCA1 and LXRβ, makes csABCA1 more susceptible to ubiquitination, and consequently facilitates its lysosomal degradation through the ESCRT system. Therefore, this molecular machinery acts to reduce HDL biogenesis in hepatocytes and promote foam cell formation of macrophages, which could exacerbate progression of atherogenesis. Future studies to identify which E3 mediates csABCA1 ubiquitination and the proteins that regulate the interaction between csABCA1 and LXRβ will expand the understanding of the molecular mechanism of csABCA1 degradation and assist the development of novel therapeutic agents designed to inhibit the progression of atherosclerotic cardiovascular disease.
ATP-binding cassette transporter A1 (ABCA1) is an atheroprotective protein as illustrated by the effects of Tangier disease, which is caused by a mutation in the ABCA1 gene and is characterized by an increased susceptibility to atherosclerotic cardiovascular disease. The turnover of ABCA1 is accelerated in hypercholesterolemia, resulting in reduced ABCA1 function and thereby progression to atherogenesis. Molecular mechanisms underlying the facilitated degradation of ABCA1 in hypercholesterolemia remain to be elucidated. Our current study shows that cell surface-resident ABCA1 is protected from ubiquitination by its physical interaction with liver X receptor β. Under conditions of high cellular cholesterol content, liver X receptor β binds to its ligands, oxygenated derivatives of cholesterol, and dissociates from cell surfaceresident ABCA1, which makes cell surface-resident ABCA1 more susceptible to ubiquitination and consequently facilitates the lysosomal degradation of cell surface-resident ABCA1 through endosomal sorting complex required for transport machinery. Our findings will help in the development of novel therapeutic agents designed to inhibit atherosclerotic progression.
Significance
